[HTML][HTML] Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa …
J Mendell, H Zahir, N Matsushima, R Noveck… - American Journal of …, 2013 - Springer
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
[PDF][PDF] Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa …
J Mendell, H Zahir, N Matsushima… - Am J Cardiovasc …, 2013 - dukespace.lib.duke.edu
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa …
J Mendell, H Zahir, N Matsushima, R Noveck… - American Journal of …, 2013 - infona.pl
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
[PDF][PDF] Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa …
J Mendell, H Zahir, N Matsushima, R Noveck, F Lee… - 2013 - researchgate.net
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
[PDF][PDF] Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa …
J Mendell, H Zahir, N Matsushima, R Noveck… - Am J Cardiovasc …, 2013 - academia.edu
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
J Mendell, H Zahir, N Matsushima, R Noveck, F Lee… - 2013 - pubmed.ncbi.nlm.nih.gov
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
[PDF][PDF] Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa …
J Mendell, H Zahir, N Matsushima, R Noveck, F Lee… - 2013 - cyberleninka.org
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa …
J Mendell, H Zahir, N Matsushima… - American Journal of …, 2013 - search.ebscohost.com
Background: Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor
J Mendell, H Zahir, N Matsushima, R Noveck, F Lee… - 2013 - hero.epa.gov
BACKGROUND: Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
J Mendell, H Zahir, N Matsushima… - American Journal of …, 2013 - europepmc.org
Background Edoxaban, an oral direct factor Xa inhibitor, is in development for
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …
thromboprophylaxis, including prevention of stroke and systemic embolism in patients with …